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Parents’ Decisions to Screen Newborns for FMR1
Gene Expansions in a Pilot Research Project
WHAT’S KNOWN ON THIS SUBJECT: Fragile X syndrome is not
diagnosed until patients are aged 3 years or older. Although
parents of affected children support newborn screening, public
acceptance of a screening test that would identify both affected
children and carriers is unknown.
WHAT THIS STUDY ADDS: In the context of a prospective,
longitudinal study in which parents are offered voluntary
newborn screening for FMR1 gene expansions, this article
reports uptake rates of parents offered screening shortly after
birth and their reasons for accepting or declining.
abstract
OBJECTIVE: The goal of this study was to document rates of parental
consent in a pilot study of newborn screening for FMR1 gene expan-
sions, examine demographic characteristics of mothers who con-
sented or declined, describe the reasons for their decision, and dis-
cuss ethical and social aspects of the consent process.
METHODS: A brief survey was used to record basic demographic data
from mothers and an open-ended question was used to elicit parents’
reasons for accepting or declining screening. A descriptive analysis
was conducted on the number of mothers who consented to or de-
clined screening, and a logistic regression model predicted mothers’
likelihood to agree to screening based on demographic characteris-
tics. Reasons for decisions were analyzed using content analysis. The
studywas conducted at University of North Carolina Hospitals. A total of
2137 mothers were approached.
RESULTS: The uptake rate for couples was 63%. Acceptance rates var-
ied by race/ethnicity, with black respondents being less likely to accept
screening. Primary reasons for accepting were “to know,” “belief in
research,” and “the test was minimal/no risk.” Reasons for declining
included not wanting to know or worry, not being a good time, and
issues with testing children or with genetic tests.
CONCLUSIONS: Findings demonstrate that a majority of parents ac-
cepted newborn screening for FMR1 gene expansions, but decision
rates and reasons for accepting or declining varied in part as a func-
tion of race/ethnicity and in part as a function of what parents most
valued or feared in their assessment of risks and benefits. Pediatrics
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State newborn screening (NBS) pro-
grams are currently the focus of public
debate and scrutiny regarding which
conditions should be added to screen-
ing panels and whether parental con-
sent should be obtained for screening
and the retention of blood spots.1–3 Re-
cent expansions of NBS and the poten-
tial for adding tests for more condi-
tions in the future have raised several
concerns, including the ethical, legal,
and social implications of including
conditions for which there are nomed-
ical treatments; labeling infants as
asymptomatic carriers or “at-risk” in-
dividuals; and disclosing findings of
uncertain medical significance, car-
rier status, or susceptibility to adult-
onset disorders.4–9 Given these con-
cerns, screening for conditions that
do not meet current NBS criteria
should only be conducted as part of a
research protocol with a rigorous
consent process clearly discussing
the risks and benefits of a positive
result.10–12
Fragile X syndrome (FXS), the most
common inherited cause of intellec-
tual disability, is an X-linked genetic
condition that exemplifies these is-
sues. FXS is caused by a CGG trinucle-
otide repeat expansion (200 re-
peats) of the FMR1 gene that, when
methylated, causes the reduction or
absence of a protein (FMRP) necessary
for normal brain development and
functioning. Absence of FMRP leads
to the overactivation of mGluR5, a
metabotropic glutamate receptor af-
fecting synaptic plasticity.13 Males with
FXS typically have moderate intellec-
tual disability and a variety of
co-occurring conditions, the most
common being anxiety, inattention, hy-
peractivity, and autism or autistic
symptoms.14 Intellectual functioning in
females can range from typical cogni-
tive abilities to moderate impairment,
a spectrum largely due to X inactiva-
tion. It is estimated that 1 per 4000
males and 1 per 6000 females have the
full mutation.15,16
The FMR1 full mutation leading to FXS
is maternally inherited either from a
carrier of a premutation (55–200 CGG
repeats) or a full mutation. The preva-
lence of the premutation is common,
estimated at 1 per 290 to 800 in males
and 1 per 129 to 259 in females.15,16 Fe-
male carriers have an elevated risk
for primary ovarian insufficiency and
early menopause17; males and, to a
lesser extent females, have an in-
creased risk for fragile X tremor
ataxia syndrome, a debilitating neu-
rologic impairment occurring after
50 years of age.18 Recent animal and
human studies have demonstrated
that some carriers may have other
neurologic or emotional problems,
suggesting a broader range of risk
and disability than has been previ-
ously assumed.14,19–22
The rationale for FXS NBS includes a
persistently delayed age of diagno-
sis23; the strong support by parents of
affected children24; and possible bene-
fits for families such as prevention of
the “diagnostic odyssey” and its finan-
cial and emotional costs; and the early
availability of information about FXS,
parents’ reproductive risks, and ap-
propriate services for the child’s spe-
cial needs.25 After weighing these and
other benefits, an American College of
Medical Genetics task force did not
recommend FXS for inclusion in state
NBS,26 however, primarily due to the
lack of a cost-effective screening test
and the absence of data on possible
benefits from identification of new-
borns. DNA-based screening for a CGG
expansion also identifies carriers,
evoking a wide range of ethical, legal,
and social concerns. Besides the cur-
rent lack of a medical treatment for
children identified with the full muta-
tion, perhaps the most fundamental
concern is triggered by the ambiguity
of the risk for carriers to have develop-
mental problems or adult-onset disor-
ders such as fragile X tremor ataxia
syndrome and primary ovarian in-
sufficiency. Presymptomatic identifi-
cation of children could lead to a
range of adverse outcomes, such as
elevated rates of postpartum de-
pression, parents’ ongoing anxiety
and worry about their child’s future,
and possible disruptions to the
parent-child relationship.2,4,11,27
Most of these risks and benefits are
not unique to FXS and apply to a wide
range of other genetic conditions likely
to be considered for inclusion on NBS
panels. Determining whether these hy-
pothesized risks and benefits are valid
can only be accomplished by examin-
ing them in a prospective screening
study. After careful deliberation of the
ethical and social implications4 and
based on our previous research with
families of children with FXS,24,28 we de-
signed a research project at the Uni-
versity of North Carolina Hospitals that
offers, through a voluntary consent
process, NBS for FMR1 gene expan-
sions. Our rationale for the study was
that there are multiple concerns and
speculations about the risks and ben-
efits of expanded screening but very
little empirical investigation. The study
uses FXS as a prototype for studying
issues such as public willingness to ac-
cept screening for conditions that are
not medically treatable or those that
would identify newborns as carriers
and/or at risk for late-onset condi-
tions, and how families adapt to ge-
netic information and to their identi-
fied child.4
We initiated the pilot study in February
2009, once a cost-effective screening
test was available.29 The screening test
identifies both the premutation and
full mutation inmales and females. The
study’s long-term aim was to follow-up
identified and matched comparison
families to assess family adaptation
and child development. In this article,
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we report findings on rates of parental
consent, examine demographic char-
acteristics of parents who consented
or declined, describe the reasons par-
ents gave for their decisions, and dis-
cuss ethical and social aspects of the
consent process. For the sake of brev-
ity and clarity, we use the term fragile
X (FX) to include both carriers (CGG re-
peat length of 55–200) and individuals




A research assistant (RA) employed by
the study approached mothers on the
postpartum unit within 24 hours of
their giving birth. Parents were given a
study brochure and consent form de-
scribing the purpose of the study, the
experimental screening test that de-
tects infants with FX, information about
the range of features expected in those
who screen positive, a detailed list of the
risks and benefits of a positive result,
and follow-up procedures including con-
firmatory testing and genetic evaluation
and counseling. (The information given
to parents can be found at www.
fpg.unc.edu/fxnewborn/. The specific
risks and benefits communicated to
parents are listed in the Appendix.)
RAs were trained to communicate this
information in a consistent manner to
all families, and were available to dis-
cuss the study in detail and answer
questions. In most cases, parents had
several hours to consider the study
before deciding. All materials were
available in Spanish, and an RA fluent
in Spanish approached Spanish-
speaking families. Mothers were not
approached if younger than age 15
years, were experiencing stressful
medical or personal circumstances,
had infants in critical care for life-
threatening conditions or relinquished
for adoption, or if not proficient in ei-
ther English or Spanish. The institu-
tional review board approved this
study under 45 CFR 46.406, requiring
consent fromboth parents “unless one
parent is deceased, unknown, incom-
petent, or not reasonably available, or
when only one parent has legal re-
sponsibility for the care and custody of
the child.” For consented newborns, an
extra blood spot obtained at the same
time as the regular NBS was placed on
a separate card and sent to a Clinical
Laboratory Improvement Amendments–
approved laboratory to conduct the
screening test. No additional heel stick
was done for this study. Parents were
informed they would receive notice of
the results within 8 weeks, by letter if
screened negative, and by a phone call
from the medical geneticist on the re-
search team if positive.
Survey and Data Collection
After deciding whether to enroll, par-
ents were asked to respond to a brief
survey with basic demographic data:
mother’s age, ethnicity/race, educa-
tion, primary language, and number
of previous births. An open-ended
question elicited parents’ reasons
for their decision to accept or de-
cline screening. Parents were not
prompted to give 1 reason, al-
though many did so. The RA recorded
their responses verbatim.
Data Analysis
A descriptive analysis was conducted
on the number of mothers who con-
sented to or declined screening ac-
cording to age, education, race/ethnic-
ity, whether English was the primary
language, and number of previous
births. These variables were used to
run logistic regression models to pre-
dict the mother’s likelihood to agree to
screening. Open-ended reasons for ac-
cepting or declining were entered into
NVivo8, a software program that facil-
itates analysis of textual data (QSR
International.com). Following estab-
lished procedures for content analy-
sis,30–32 the first and second author in-
dependently read the first 1000
responses, and devised codes sub-
suming each response. This coding
scheme was refined through compari-
son, discussion, and application of
codes in an iterative process, and the
final codes were then used to catego-
rize all responses. Two coders inde-
pendently coded responses and com-
pared coding. Any discrepancies in
coding were reconciled through re-




Between February 2009 and April 2010,
study recruiters approached 2137
mothers. Of these, 2045 (95.7%) were
willing to hear about the study. About
two thirds (67.5%) of the 2045 con-
sented to have their newborn
screened. Because some fathers ac-
tively declined screening (n  16) or
failed to return a signed consent form
(n  76) after the mother consented,
the rate of consent for couples
dropped to 63%. Of the 2045 mothers,
1930 filled out the brief survey, provid-
ing basic demographic information for
1381 acceptors and 549 decliners
(Table 1). Of the 115 who did not fill out
the brief survey, 114 were decliners.
The project was conducted at a uni-
versity research and teaching hospi-
tal serving a diverse population, in-
cluding lower-income families and
Latino immigrants as well as univer-
sity faculty and students. Of the
mothers, 37% were Latino/Hispanic,
almost all of whom were Spanish
speakers; 43.7% were white; and
13.4% black. As for education, 44.2%
had a high school education or less
while 21.1% had postgraduate or
professional degrees.
When looking at screening decisions
by race/ethnicity alone, black mothers
were less likely to agree to screening
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(63.7%) than Hispanic (71.6%) or white
(75.4%) mothers. A logistic regression
model to predict a mother’s likelihood
to agree to screening used maternal
variables of ethnicity/race, marital
status, education, age, and number of
previous births. Results are reported
in Table 2. In this model, black respon-
dentswere about half as likely to agree
as either Hispanic (odds ratio: 0.55) or
white (odds ratio: 0.52) respondents.
Those classified as “other” were about
one third as likely to agree as white
respondents. Education was mea-
sured as a categorical variable with 5
levels: less than high school, high
school, some college, college degree,
and graduate degree. In general, edu-
cation was positively related to willing-
ness to participate; as education in-
creased, so did willingness. However,
only 1 of the pairwise comparisons be-
tween levels was significant: those
with graduate degrees were more
likely to agree to participate than
those with less than a high school
diploma.
Reasons for Accepting or Declining
The content analysis including catego-
ries, frequencies, and representative
comments for the reasons parents
gave for their decisions is reported in
Table 3. The most prevalent reason, by
far, given by acceptors was “to
know” (71.6%). Parents indicated they
wanted to know to monitor their
child’s health and development, and to
plan ahead. Most comments were sim-
ilar to the parent who said, “Cause I
believe that every test can help. I’d
rather knowmore than less. It can give
us a jump start if something is wrong,
to help her get better.” Almost one
third cited a belief in research as a
reason for consenting. For example, 1
mother wanted to participate “to fur-
ther knowledge, to help with re-
search.” Another mother viewed par-
ticipation as a social responsibility,
saying “You can’t find cures for dis-






Mean age, y 28.4 28.7 t .88
Marital status, % 22 1.59
Single, never married 39.5 38.1
Married 57.6 59.9
Previously married 2.8 2.0
Education, % 24 3.74
High school 28.2 30.8
High school degree 15.4 14.6
Some college 17.1 17.9
College degree 17.0 18.2
Postgraduate degree 22.1 18.6









Gender of newborn, % 21 .90
Male 51.7 49.3
Female 48.3 50.7







TABLE 2 Relationship Between Selected Maternal Demographic Variables and Acceptance of FXS
NBS
Variable OR (SE) CI 2
Asian vs black 1.27 (0.37) 0.72 to 2.24 0.67
Asian vs Hispanic 0.69 (0.20) 0.39 to 1.22 1.59
Asian vs other 1.99 (0.87) 0.85 to 4.68 2.49
Asian vs white 0.66 (0.17) 0.40 to 1.08 2.69
Black vs Hispanic 0.55 (0.10) 0.38 to 0.78 10.71a
Black vs other 1.57 (0.61) 0.74 to 3.35 1.36
Black vs white 0.52 (0.09) 0.38 to 0.72 15.51b
Hispanic vs other 2.88 (1.12) 1.34 to 6.18 7.34a
Hispanic vs white 0.95 (0.16) 0.69 to 1.31 0.09
Other vs white 0.33 (0.12) 0.16 to 0.68 8.89a
Single vs married 1.27 (0.16) 0.98 to 1.64 3.34
Single vs previously married 0.78 (0.28) 0.38 to 1.59 0.48
Married vs previously married 0.61 (0.22) 0.30 to 1.24 1.84
high school vs high school degree 0.77 (0.14) 0.54 to 1.09 2.17
high school vs some college 0.74 (0.14) 0.51 to 1.08 2.49
high school vs college degree 0.71 (0.16) 0.46 to 1.09 2.45
high school vs graduate degree 0.53 (0.13) 0.33 to 0.84 7.16a
High school degree vs some college 0.96 (0.18) 0.67 to 1.39 0.04
High school degree vs college degree 0.92 (0.19) 0.61 to 1.39 0.16
High school degree vs graduate degree 0.69 (0.15) 0.44 to 1.06 2.82
Some college vs college degree 0.96 (0.18) 0.66 to 1.38 0.06
Some college vs graduate degree 0.71 (0.14) 0.48 to 1.06 2.83
College degree vs graduate degree 0.75 (0.13) 0.53 to 1.04 2.91
Mother’s age 0.99 (1.01) 0.97 to 1.01 .69
No. of live births 0.97 (1.05) 0.89 to 1.06 0.41
OR indicates odds ratio; CI, confidence interval.
a P .01.
b P .001.
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TABLE 3 Couples’ Reasons for Accepting/Declining NBS
n (%)a Representative Responses
Reasons for accepting (n 1288)
Knowing is good/there is benefit to knowing/knowing earlier is
better
922 (71.6) “More information is always a bonus. I’d rather know about stuff.”
“I believe in early intervention kind of stuff. No better way to
prepare your future than to know up front.”
To contribute to research 412 (32.0) “We’re happy to do it if it benefits research.”
“I want to support research.”
The test is minimal risk/noninvasive/just an additional test 354 (27.5) “It’s non-intrusive; an additional drop of blood is not much.”
“There are no risks; he’s being pricked already.”
Participating cannot hurt/nothing to lose 108 (8.4) “Figured it would be a good thing to do. Not much reason not to.”
“I don’t see any reason why I wouldn’t do it.”
My family has a history of problems 76 (5.9) “In our family we have these types of problems.”
“I have a cousin like this with mental retardation.”
The screening is free 60 (4.7) “Extra screening is always a bonus, especially if it’s free.”
“It is good to get a free test. You won’t hurt the child and it’s free.”
Just curious 27 (2.1) “Just curious. Better safe than sorry.”
“Curiosity is a big factor for me.”
Spouse/partner convinced me 27 (2.1) “Main reason is my husband is a scientist and he knows it is
important. I agree with him and believe him.”
Because the screen was offered 18 (1.4) “Because it was offered. We have the opportunity.”
“Why not if it’s something that’s offered. He’ll be tested for 50
other conditions.”
To provide reproductive risk information 8 (0.6) “We think it would be good for him to know for when he has
children.”
“To decide whether to have more children in the future.”
Reasons for declining (n 565)
Logistics (the context, the timing is not good) 121 (21.4) “Not right now. I’m participating in lots of studies. The traffic in
and out (of the room) has been non- stop.”
“We’re not too comfortable with it at this time. We’re bombarded
with a lot right now.”
Do not want to worry 121 (21.4) “Because I want to believe that everything is OK; I don’t want to
worry.”
“At this stage, we feel information would cause more stress than
be helpful.”
Issues regarding testing 109 (19.3) “The baby is tested for enough things already. Too much testing
can make one paranoid.”
“I’m not interested in extra testing. I had no prenatal testing
either.”
Do not want to know 100 (17.7) “At this point I don’t really want to know if there’s anything and I
don’t want to know if I passed it.”
“I don’t want to because I don’t want to know if he has a problem.”
Do not want to be in study/not interested 84 (14.9) “I’m not the study participant type.”
“I’m not interested.”
It is not necessary 78 (13.8) “No, I think the regular screening you are talking about is enough.
We don’t think the other is necessary.”
Little chance of having it/no family history 70 (12.4) “It’s not something we’re worried about. No genetic
predisposition. We already have a healthy child. There’s no one
in our family with mental retardation.”
“Neither us nor the family has this type of syndrome; we don’t
think she can inherit it.”
Spouse/partner declined or disagreed 65 (11.5) “I would have liked to have done it, to know and be prepared in
case he has it, but my husband doesn’t want to.”
My baby is fine/healthy 62 (11.0) “I think God made her a healthy baby. I believe she will be
perfectly fine.”
“She looks pretty healthy to me; I know nothing is wrong.”
I would rather wait for symptoms to appear 53 (9.4) “I would rather not know since I don’t know when it will kick in. I’d
rather not know and find out later when it happens.”
“If he’s going to have mental retardation, then we’ll deal with it
when it happens. There’s no point in knowing now.”
There is no cure or treatment 30 (5.3) “Not interested because there’s no cure.”
a Based on number of couples providing reasons for their decisions. Some families’ gave1 reason, thus percentages total100%.
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eases without doing these things. It’s
your social responsibility. Try to help
out all you can.” The only other pre-
dominant reason, given by more than
one fourth of the acceptors, was that
the study was noninvasive, posingmin-
imal or no risk to the child.
Reasons for declining were more
equally distributed and included not
wanting to worry about the test result
(21.4%), negative feelings about test-
ing children or genetic testing in gen-
eral (19.3%), and not wanting to know
(17.7%). About one fourth noted that
the timing or context for deciding was
not good. Decliners voiced the same
concerns that bioethicists and others
have raised about NBS. One mother
said, “Knowing can cause anxiety. The
chances of it happening are very small;
don’t know how it will unfold. Not
knowing will not make you treat your
child a certain way.” Another mother
declined “because I don’t feel comfort-
able. I would rather not know since I
don’t know when it will kick in. I don’t
want to stress over the test results. I’d
rather not know and find out later
when it happens.” Those who indicated
a distrust of or opposition to tests in
general made comments like, “I just
didn’t want an extra test because we
didn’t do any extra tests with the preg-
nancy,” “The infant is tested for
enough things already,” and “Too
much testing can make one paranoid.”
Both an advantage and a risk of
screening for FX, depending on one’s
perspective, is that identifying a new-
born with an altered FRM1 gene pro-
vides information to parents that one
of them has a substantially increased
risk for having children who are either
carriers or have FXS. Although this
knowledge was presented as both a
benefit and risk in the consent form,
only 8 parents noted “to provide repro-
ductive risk information” as a reason
for accepting.
DISCUSSION
This pilot project was not designed to
maximize uptake but rather to exam-
ine the extent to which parents accept
or decline screening within the context
of a written consent process that ex-
plicitly stresses the risks and benefits
specific to learning whether their new-
born has an expanded FMR1 gene. The
acceptance rate of 63% is consider-
ably lower than those reported in
other NBS pilot projects33–35 and lower
than the 79% rate reported in a pilot
study that offered FX screening for
male newborns in South Carolina.36 Ac-
ceptance rates are likely to vary de-
pending on the timing, content, and ex-
tent of the consent process, whether
consent is oral or written or opt in or
opt out, the type of disorder, and
whether treatments exist.35 In this
study, the acceptance rate is not sur-
prising considering that the screening
test detects a condition with no cure,
discloses carrier status for which pre-
dictive information is equivocal, and is
preceded by a rigorous consent pro-
cess, generally requiring both parents’
consent, conducted in the hospital
within 24 hours of birth. One concern
about pilot studies offering informed
consent for NBS is that parents may
begin to question or choose to opt out
of state NBS. There were no cases of
that happening in this study.
In a previous article, we examined pos-
sible challenges to an informed con-
sent process in screening for FX in the
neonatal setting.4 These challenges in-
cluded the ability to adequately explain
the potential consequences of having
FXS or of being a premutation carrier,
and the possible ramifications of a
positive diagnosis for the family, in-
cluding confirmatory testing and ge-
netic counseling. Although we de-
signed educational and consent
materials to convey this information,
and RAs were trained to explain and
discuss the study and FX in more de-
tail, the reasons some parents gave, or
did not give, indicate that they may not
have fully understood the study or FX
and its personal, familial, and so-
cial consequences. For example, the
mother who indicated she consented
to the screening to help to find cures
for diseases may have misunderstood
the purpose of the study. Parents who
gave as a reason for consenting “to
help my child get better” may have not
understood that there is no cure or
standard medical treatment or they
may have been referring to early-
intervention services. Those who de-
clined the study because the infant
looked healthy or there were no prob-
lems in their family may not have un-
derstood how FX is inherited or mani-
fests, but they may also have not
wanted to consider that something
could be wrong with their newborn.
The lack of responses about a positive
result providing information on repro-
ductive risk or possible medical condi-
tions in adult carriers is likely due to
parents at this time focusing more on
the implications of a positive diagnosis
for the newborn and not what this in-
formation would mean for others.
About one fourth of thosewho declined
also indicated that the timing and con-
text of consent were not optimal, rais-
ing the issue of the most appropriate
time for consent and screening. Par-
ents’ opinions about these issues war-
rant additional study. We are currently
conducting interviews with a subset of
decliners and negatively screened ac-
ceptors to examine inmore detail their
evaluations of the consent process, un-
derstanding of the information pre-
sented, and reasons for their decision.
We are also assessing the positive
screened families to ascertain their
responses and experiences related to
the diagnosis.
For themost part, the reasons given by
the vast majority of parents for accept-
ing or declining suggest that they were
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assessing many of the risks and bene-
fits of the study and were making deci-
sions based on what they most valued,
or perhaps most feared. Although ac-
ceptance rates were lower than other
NBS pilot studies, almost two thirds of
families consented, indicating more
parental support for testing for FMR1
gene expansions in the newborn pe-
riod than reported among pediatri-
cians or genetic counselors.37,38 This is
consistent with studies that indicate
parents may view the benefits of ex-
panded screening more broadly than
defined by current criteria for NBS and
are supportive of such screening with
informed consent.39 Our findings also
indicate some difference in accep-
tance rates according to race/ethnic-
ity, with black respondents somewhat
less likely to consent to screening.
This may be due to mistrust rising
from the historical legacy of medical
and genetic research in the United
States with blacks40–42 or to a differ-
ent valuing of the benefits and risks of
screening. We cannot answer this
question from our data but acknowl-
edge that the role of race/ethnicity ver-
sus cultural differences in medical de-
cision making is complex and requires
additional investigation.
During the course of this pilot project,
studies that could fundamentally
change the rationale and need for NBS
have been reported. These include
studies showing that compounds re-
ducing excess glutamate signaling
substantially improve functioning in
fmr1 knockout mice43 and Drosoph-
ila.44 In addition, human clinical trials
with adolescents and adults with FXS
are now testing the effects of
medications known to reduce mGluR-
activated translation.45–48 Because FXS
affects neurologic processes neces-
sary for normal development and
learning in the early years, these treat-
ments (if shown to be safe and effec-
tive for young children) would likely be
most effective if given early. However,
the fact that carriers would be identi-
fied suggests that parent consent for
screening for FXS will still be required.
In anticipation of this scenario, more
research is needed comparing and
contrasting alternative strategies and
times for informing families so that
they can make informed decisions
about having their child screened.
CONCLUSIONS
Our findings contribute empirical data
on public willingness to participate in
NBS for FMR1 gene expansions. Results
indicate that almost two thirds of par-
ents support FXS screening in the neo-
natal context, and parents’ reasons for
accepting or declining suggest some
understanding of the benefits and
risks of the study. As for most re-
search projects, we cannot determine
if truly informed consent was obtained
but have demonstrated that although
not the ideal time or place, it is possi-
ble to obtain informed consent in a
neonatal context. Alternative consent
strategies need to be considered but
of ultimate importance will be the im-
pact of the information on families
who receive a positive diagnosis, in-
cluding those individuals who may be
asymptomatic carriers.
APPENDIX: RISKS AND BENEFITS
LISTED IN CONSENT FORM AND
BROCHURE
Benefits to Infants Identified as
Having FXS or Being a Carrier May
Include:
The diagnostic testing, genetic coun-
seling, clinical evaluation, and refer-
rals provided by the study.
Eligibility for certain learning and ther-
apeutic services that may be helpful to
the infant.
Alerting parents to the future health or
learning problems the infant may
have.
Preparing parents to raise a child with
special needs.
Benefits to Parents of Infants
Identified as Having FXS or Being a
Carrier May Include
Saving financial and emotional costs of
many trips to physicians to find out the
cause of their child’s problems.
Getting the early-intervention services
the child may need.
Information that they and their rela-
tives may be at risk for having children
with FXS.
Getting support services that may be
helpful to them.
Risks of Being in the Study
There may be a small emotional risk;
you might worry about whether the in-
fant’s screening in the study will show
a need for more testing.
Learning that one’s infant has FXS may
bring about feelings of grief, a sense of
loss, worry, or anxiety. It may cause
some stress in the family.
Learning that one’s infant has FXS may
cause parents to worry about what the
condition will mean for the infant and
family.
If an infant has the gene change for FXS,
itmeans that one of the parents also has
the gene change. Parents may feel bad
about passing on that gene change. They
may worry that other children or family
members need testing.
There may be some stigma associated
with learning there is an inherited ge-
netic condition in one’s family.
Although there are laws to protect
genetic information, you may worry
about how others could use this in-
formation. Discrimination against
your family or child by insurance
companies, employers, or schools
could be possible.
Finally, although unlikely, the study
screening test result could bewrong. It
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may show that infants need more test-
ing when they do not or it may not find
infants with FXS. If your infant has
health or developmental problems
later, he or she may need diagnostic
testing for FXS.
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